Autopsy report · NCT06021600

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

“Slow participant enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 5 months before it stopped.
• 3 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Leukemia; Myelodysplastic Syndromes; Acute Myeloid Leukemia

Interventions

Cladribine

Participants

3

Sites

1

Countries

United States

Trials that died the same way

• Comparison Study of Two Splints Used for Treatment of Acute Temporomandibular Pain.
  “Very slow enrollment of participants” (96% match in meaning)
• Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)
  “slow enrollment” (92% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.